Understanding antimicrobial (AM) usage is key to safely reducing AM use in food-producing animals as part of addressing the global public health threat of AM resistance. We estimated intramammary AM usage from national sales data for the period 2003 to 2019, updating an earlier work. Descriptive trends in AM use are presented. We observed some reduction in dry cow AM use when accounting for cow numbers; however, use of blanket dry cow therapy is still widespread. In addition, there is evidence of ongoing use of highest priority critically important AM. This study provides objective evidence in support of efforts to direct and prioritize urgent changes in AM prescribing and usage as well as securing farm-and prescriber-level data in Ireland. Highlights• Blanket use of dry cow AM therapy is still very common in the Republic of Ireland.• There is evidence of ongoing use of highest priority critically important AM.• We identify key knowledge gaps and areas for urgent review in AM prescribing practices and acquiring prescriber-and user-level data.

Background Selective dry cow therapy (SDCT) is widely promoted in dairy farming as a method to reduce antimicrobial usage. New legislation introduced by the European Union will restrict and regulate the prophylactic and metaphylactic use of antibiotics from January 2022. Blanket dry cow therapy continues to be a practice engaged in by many farmers in Ireland and for many of these farmers, moving towards SDCT would require a significant infrastructural, behavioural and/or cultural change on their farm. Existing research has reported the important need to understand farmers’ motivations to initiate any substantial behaviour change. However, it is currently unknown what farmers know, think and believe about SDCT in Ireland. The aim of this study was to use qualitative methods to explore what barriers and facilitators farmers perceived to exist with SDCT and explore if they had chosen to implement SDCT after voluntarily participating in a funded dry cow consult with a trained veterinarian, with the objective of maximising the dry period udder health performance and moving safely to SDCT. Results In this study, 19 farmers were contacted, and telephone interviews were conducted regarding farmers’ beliefs about the consequences of SDCT. Audio recordings were professionally transcribed verbatim and analysed qualitatively using an inductive thematic analysis. The analysis identified 6 barriers and 6 facilitators to implementing SDCT. A significant fear of increasing mastitis incidence was evident that caused reluctance towards SDCT and reliance on antibiotics. Mixed perceptions on SDCT, infrastructure limitations, a perceived lack of preventive advice as well as peer influence were presented as barriers to SDCT. Farmers can build confidence when a graded approach to SDCT is implemented, which could help overcome the fear of SDCT and reliance on antibiotics. Regulatory pressure, high standards of farm hygiene and use of targeted veterinary consults were found to facilitate SDCT. Education was suggested to motivate farmers in the future uptake of SDCT. Despite cited negative influences, peer influence can be utilised to encourage the farming community. Conclusions This study prioritises areas to facilitate the major behaviour change required as a dairy industry in order to move from blanket dry cow therapy to SDCT.

No abstract

Background: Congenital heart diseases are occasionally encountered in the bovine species. Ventricular septal defects (VSD) and atrial septal defects (ASD) are reported to be the most common; however, a vast collection have been reported [1, 2]. Congenital heart diseases is thought to represent less than 3% of all congenital abnormalities in calves [3]. Various cardiac anomalies arise due to defective embryologic development such as defects of the septae or the cardiac chambers [2]. The exact aetiology of these congenial heart anomalies remains to be fully elucidated [4]. VSDs appear to be the most common congenital cardiac anomaly in calves. Other diseases can be subdivided into cyanotic (e.g. ASD or patent ductus arteriosus) and non-cyanotic (e.g. tetralogy of fallot or eisenmengers complex) [5, 6]. An exceptional presentation of an array of congenital anomalies was identified in a Friesian heifer calf. To the authors' knowledge this concurrent collection of congenital abnormalities has never been reported in this species. Case presentation: A 3-day old Friesian heifer presented with a history since birth of regurgitation post feeding. The main finding on clinical examination was tachypnoea with a holosystolic murmur. Echocardiography identified a VSD, patent foramen ovale (PFO) (both with left to right blood flow) and tricuspid insufficiency. The calf was subsequently euthanised and underwent gross post-mortem examination. A persistent right aortic arch (PRAA) was identified. The cardiac anomalies identified on the echocardiogram were confirmed along with additional abnormalities; double outlet right ventricle (DORV), partial transposition of the great vessels, pulmonic stenosis, hypoplasia of the right branch of the pulmonary artery and right ventricular hypertrophy. The final diagnosis was Tetralogy of Fallot with DORV, PFO and PRAA. The lungs appeared oedematous and congested due to cardiac malfunction and cranioventral aspiration pneumonia. Free serous fluid was identified in the thoracic cavity. Unilateral renal agenesis of the left kidney was an incidental finding but is of note due to its coexistence with the cardiac abnormalities.

Intramammary (IM) antimicrobial sales data are currently the only feasible means to gain broad insights into on-farm usage of antimicrobials (AMs) relevant to mastitis control within the Irish dairy industry. The aim of this study was to update earlier work describing sales data of intramammary antimicrobial usage in the Irish dairy industry in 2020. Previously reported data from 2013 to 2019 is included for reference and 2020 sales data is reported using similar methodology to previously published work in this area. Data on IM AMs sold in Ireland during 2013-2020 were obtained from two sources, believed to represent 99% of all sales of IM AMs in Ireland, and analyses were undertaken to evaluate patterns in IM AM sales. We report an increase in overall sales of both lactating cow (LC) and dry cow (DC) IM AMs. We observed a large increase in the use of DC IM AMs, from 0.95 to 1.13 defined course dose (DCDvet) per cow per year in 2019 and 2020 respectively, as well as evidence of ongoing usage of highest priority critically important AMs, as defined by the World Health Organization. There was also a slight increase in LC use of IM AMs, from 0.43 to 0.44 defined course dose (DCDvet) per cow per year. We believe that our results provide an accurate reflection of IM sales in Ireland in 2020. In common with any study of this type, caution is needed when interpreting national IM AM sales data, noting the potential discrepancies between AM sales and on-farm usage. Nonetheless, the sales pattern described here, most importantly the increased use of DC products and ongoing and increasing use of HP CIA products in both DC and LC therapy raise significant concerns for the Irish dairy industry. This study provides an evidence base to inform current policy discussions, particularly in the context of the new Veterinary Medicines Regulation (Regulation (EU) 2019/6), which comes into force on 28 January 2022.